The Institute of Cancer Research London recently sponsored the plasmaMATCH study—showcasing the Guardant360's ability to evidence 96-99% overall concordance with digital droplet PCR (ddPC) liquid biopsy, an orthogonal method. The plasmaMATCH Study The largest-ever...